Lilly acquires Centessa Pharmaceuticals to enhance sleep-wake disorder treatments
Eli Lilly has completed its acquisition of Centessa Pharmaceuticals, focusing on orexin receptor 2 agonists.
Indication
Clinical and regulatory intelligence for Sleep-Wake Disorders with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.